New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
07:32 EDTBMY, JNJ, GSK, SNYMajor drug firms create pact for medicine development, WSJ reports
Ten major drug companies formed a pact for five years to cooperate on a government-backed effort with the National Institutes of Health to speed up the discovery of new medicines, reports the Wall Street Journal. Reference Link
News For BMY;JNJ;GSK;SNY From The Last 14 Days
Check below for free stories on BMY;JNJ;GSK;SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 9, 2014
11:43 EDTBMYGilead defended by analysts after recent pullback
Subscribe for More Information
07:23 EDTJNJ, BMYEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
07:09 EDTSNYReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Subscribe for More Information
07:09 EDTJNJJohnson & Johnson outlook positive into Q1 results, says Bernstein
Bernstein expects Johnson & Johnson's Q1 EPS to come in slightly above the consensus estimate, with strength in pharmaceuticals more than offsetting lackluster Medical Devices & Diagnostics growth, according to the firm. Bernstein keeps an Outperform rating on the stock.
April 8, 2014
11:03 EDTBMY, SNY, GSKPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
08:46 EDTGSKTeva announces first approval, launch of generic Lovaza capsules in the U.S.
Teva (TEVA) announces the approval of the generic equivalent to Lovaza in the United States. Teva believes it is first-to-file and thus far is the only company to receive an approval from FDA. Teva plans to commence shipping immediately. Lovaza Capsules, marketed by GlaxoSmithKline (GSK), had annual sales of approximately $1.1B in the United States, according to IMS data as of December 2013.
07:26 EDTJNJElsevier Business Intelligence to hold a conference
Subscribe for More Information
07:22 EDTGSKCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
April 7, 2014
14:18 EDTGSKGlaxoSmithKline reports 14.1% stake in Applied Genetic Technologies
Subscribe for More Information
08:06 EDTBMYBristol-Myers submits NDAs for Daclatasvir and Asunaprevir to FDA
Subscribe for More Information
05:28 EDTSNYGenzyme to resubmit Lemtrada application for FDA review
Subscribe for More Information
April 6, 2014
16:23 EDTGSKGlaxoSmithKline investigates bribery allegations in Iraq, WSJ says
GlaxoSmithKline is investigating allegations of bribery by employees in Iraq, says the Wall Street Journal, citing emails reviewed by the publication. Reference Link
April 4, 2014
06:29 EDTGSKGlaxoSmithKline cuts China employees amid probe, WSJ reports
According to a source, as it deals with a bribery probe in Beijing, GlaxoSmithKline is cutting employees in China, the Wall Street Journal reports. It is unclear how many of Glaxo's 7,000 employees in China have been let go. Reference Link
April 3, 2014
09:37 EDTGSKAmgen to pay GlaxoSmithKline $275M to terminate denosumab collaboration pact
Subscribe for More Information
06:36 EDTSNYSanofi on lookout for acquisitions, expects growth in Africa, Reuters says
Subscribe for More Information
April 2, 2014
09:18 EDTGSKOn The Fly: Pre-market Movers
Subscribe for More Information
08:40 EDTJNJPiper Jaffray to hold booth tours
Booth Tours at SAGES Annual Meeting will be held in Salt Lake City, Utah on April 2-3.
07:44 EDTGSKAgenus down 9.4% after GlaxoSmithKline stops MAGRITi Phase 3 trial
Subscribe for More Information
06:11 EDTGSKGlaxoSmithKline confirms plans to stop MAGRIT Phase III trial
GlaxoSmithKline announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. Data from the trial announced on 20 March 2014 showed that it did not meet its first or second co-primary endpoints as it did not significantly extend disease-free survival when compared to placebo in either the overall MAGE-A3 positive population or in those MAGE-A3-positive patients who did not receive chemotherapy. The trial will be stopped and GSK will now gain access to the un-blinded data, in order to conduct a full assessment of the findings and understand learnings for other aspects of immunotherapy development within GSK. The Independent Data Monitoring Committee indicated that its review of the current safety information revealed no specific safety concern and the data is in line with the known safety information for the MAGE-A3 cancer immunotherapeutic.
05:45 EDTGSKAgenus announces GSK's MAGE-A3 Phase 3 study will be stopped
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use